Agenda
*All times are listed in local time zone (CT)
6:00 AM – 6:30 AM Registration
6:30 AM – 6:35 AM Welcome and Opening Remarks
6:35 AM – 6:55 AM Overview of CKD in T2D
6:55 AM – 7:15 AM MR Blockade to Treat T2D-Associated CKD
7:15 AM – 7:45 AM Patient Selection, Multidisciplinary Care, and Overcoming Clinical Inertia
7:45 AM – 8:00 AM Question and Answer Session
Events
Date / Time
Event Details
Faculty
Faculty
Diana Isaacs, PharmD, BCPS, BCACP, CDCES, BC-ADM, FADCES, FCCP
Endocrine Clinical Pharmacy Specialist
CGM and Remote Monitoring Program Coordinator
Endocrinology and Metabolism Institute
Cleveland Clinic
Cleveland, Ohio
Faculty
Joshua J. Neumiller, PharmD, CDCES, FADCES, FASCP
Vice-Chair & Allen I. White Distinguished Professor
Department of Pharmacotherapy
College of Pharmacy and Pharmaceutical Sciences
Washington State University
Spokane, Washington
Program Overview
The program will provide an overview of CKD in type 2 diabetes, and expert insights on the evidence behind the use of finerenone in diabetic kidney disease, selecting appropriate patients for finerenone therapy, and strategies for overcoming clinical inertia.
Goal Statement
The goal of this activity is to improve the knowledge and competence of pharmacists about pathophysiology of mineralocorticoid receptor activation in CKD in patients with T2D and the impact of the selective nonsteroidal mineralocorticoid receptor antagonist finerenone on patient care.
Target Audience
The target audience for this activity is pharmacists, including community, ambulatory care, primary care, and clinical pharmacists, who care for patients with CKD and T2D as well as pharmacy directors, chief pharmacy officers, and other stakeholders in pharmacy practice.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the pathophysiology and renal and cardiovascular outcomes of mineralocorticoid receptor activation in chronic kidney disease in patients with type 2 diabetes
- Evaluate the safety and efficacy evidence of the selective nonsteroidal mineralocorticoid receptor antagonist finerenone
- Compare the clinical differences between steroidal and selective nonsteroidal mineralocorticoid receptor antagonists
- Identify appropriate candidates for finerenone and strategies to implement use, including multidisciplinary care and overcoming clinical inertia
Accreditation
CE Accreditation
Pharmacists

ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-22-093-L01-P has been assigned to this live application-based activity (initial release date 3-20-22). This activity is approved for 1.5 contact hours (0.15 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Participants must complete the online post-test and activity evaluation within 30 days of the activity to receive pharmacy CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles.
Disclosure
ProCE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to ProCE policy. ProCE is committed to providing its learners with high-quality CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. Faculty disclosures will be provided prior to the start of the CE activity.